Home › Forums › Clinical Practice › GLP-1 use in ED-recovered patient with IR

Viewing 3 posts - 1 through 3 (of 3 total)
  • Author
    Posts
  • #1485
    Monica Peralta

      Hi all,

      I’m seeking clinical input from this group regarding a patient I’ve been working with who presents a complex intersection of metabolic markers and eating disorder history. I’d be grateful for any insights.

      25-year-old cis woman, in full recovery from BN for 4 years. She’s active, has a stable and flexible relationship with food, and has done significant work on body image. Currently under the care of a diabetologist for insulin resistance. No current bingeing or purging behavior.

      Recently had a single binge episode triggered by a restrictive “high-protein day” suggested by her provider, which we managed clinically.

      The dilemma: Despite no current binge eating and overall food stability, her provider has initiated semaglutide, citing it helps “impulsivity with food.” The patient is scared of “becoming diabetic” and consented out of fear, not from informed choice. Her ED history and her emotional distress in the session make me concerned.

      My questions for you all: What is your take on semaglutide in a case like this—no diabetes, only IR, with history of BN?Have you seen harm or benefit from GLP-1s in ED-recovered patients, even in the absence of BED? What evidence-based interventions have you used to support metabolic health while centering ED recovery and body trust?

      Any input would be hugely appreciated.

       

      #1486
      Dr. Erin Knopf

        Sounds like a consultation with the other provider is warranted. In these cases, I find “seeking to understand” by being curious can help point out whether this is a worthy use of the medication or not. If “impulsivity with food” was the reason for the recommendation, is the patient endorsing that? If not, how did the other provider form the recommendation? Psychoeducation about the imminent risk of ED relapse if nutritional intake is interfered with (whether from physical aversion to food, decreased intrinsic signals, decreased oral intake with early satiety). In that discussion for Risk/ Benefit, perhaps the other provider will change the recommendation.

        #1488
        Monica Peralta

          Thank you Dr. Erin!

        Viewing 3 posts - 1 through 3 (of 3 total)
        • You must be logged in to reply to this topic.